EREBRAL cavernous malformation represents a brain and spinal cord vascular disorder characterized by abnormally dilated vascular channels lined by a single layer of endothelium. Histological examination of these lesions demonstrates dilated capillary beds without intervening neural structures or smooth muscle, as well as hemosiderin deposits indicating prior hemorrhage.
toms. 19 Symptomatic patients typically present with seizures, stroke, headaches, or, rarely, frank hemorrhage. The causes of such a diverse presentation among patients suffering from CCMs remains unclear, and little is known regarding the molecular pathogenesis of the disease.
Ten to twenty percent of caucasian patients with CCM have a first-degree relative with the disease; this proportion increases to 50% among Hispanic Americans, representing a 20-to 100-fold increase in risk compared with the general population. 13 These findings suggest that genetic factors contribute to the pathogenesis of CCM, and an initial linkage analysis in Hispanic-American families has localized a gene causing CCM, CCM1, to chromosome 7q21. 7, 10 Subsequent studies have demonstrated a founder effect among both familial and apparently sporadic cases in this population, proving that all these persons have inherited an identical mutation from a common ancestor, 12 refining the linked region to a 4 cM interval at 7q21.
14 Positional cloning experiments have ultimately identified one of the genes located in this region, KRIT1, as the CCM1 gene. 1, 2, 4, 6, 15, 17, 21, 23, 24, 27 The function of the KRIT1 protein is unknown. The KRIT1 gene was incidentally cloned using a yeast two-hybrid screen with Krev1 (Rap1A) as bait. A small guanosine triphosphatase with significant homology to Ras, Krev1 is thought to act as a tumor suppressor gene within the Rassignaling cascade. 22 Thus KRIT1 is an acronym for the Krev Interaction Trapped 1 gene.
A mutational analysis of KRIT1 in affected HispanicAmerican kindreds has demonstrated the founder mutation to be 2105C➝T, which inserts a stop codon in exon 14. 15, 21 Although this founder mutation in KRIT1 is responsible for virtually all CCM cases among Hispanic Americans of Mexican descent, mutations in KRIT1 only account for approximately 30% of CCMs among non-Hispanic cases. 12 Subsequent genome-wide linkage studies in this latter population identified two additional loci, CCM2 on 7p and CCM3 on 3q. 5 The CCM2 and CCM3 genes are not yet known and the phenotype of patients of all three loci is clinically indistinguishable.
In this study we screened for mutations in KRIT1 in 21 Hispanic and 47 non-Hispanic kindreds with a family history of CCM, as well as in 35 Hispanic and 103 non-Hispanic persons whose CCM is apparently sporadic.
Clinical Material and Methods

Reverse Transcription-PCR
Whole-cell RNA was extracted from lymphocyte cell lines by using Trizol reagent according to the manufacturer's protocol (Gibco BRL, Gaithersburg, MD). Complementary DNA was generated by adding 1 l of Oligo-dT primer to 1 g of whole messenger RNA with the aid of M-MuLV reverse transcriptase (Roche Applied Sciences, Indianapolis, IN). Polymerase chain reaction was performed on 2 l of reverse transcription reaction agent with primers designed to amplify a segment of the transcript covering both the newly identified coding sequence and the published KRIT1 sequence. The resulting amplicon was sequenced using dideoxyribonucleotide chain termination on a DNA sequencing system (ABI 373 instrument; Applied Biosystems, Framingham, MA).
Family Collection
This study was approved by the Human Investigation Committee at Yale University (Protocol No. 7680) . At the present time we have recruited a total of 961 individuals from 206 families ( Figs. 1 and 2 ). Index cases were collected and screened rigorously for a family history based not only on CCM lesions, but also on history of stroke or seizure, and/or positive findings on a magnetic resonance image. Fourteen of 21 Hispanic kindreds with a positive family history, 10 of 34 Hispanic persons with apparently sporadic CCM, and 20 of 47 non-Hispanic familial cases were reported on previously.
5,11
Preparation of Genomic DNA Ten milliliters of venous blood was collected in tubes containing either acid citrate-dextrose or ethylenediamine tetraacetic acid and was shipped at ambient temperature by overnight courier to the laboratory. The DNA was prepared from whole blood by lysis of nuclei, which was accomplished using sodium dodecyl sulfate and proteinase K, followed by phenol-chloroform extraction and ethanol precipitation. The DNA was resuspended in water containing 10 mM Tris (pH 8) and 0.1 mM ethylenediamine tetraacetic acid. Samples were aliquoted and diluted to 200 g/ml, after which they were frozen at Ϫ80˚C.
Linkage Analysis
Index cases were initially collected and screened using mutational analysis for KRIT1 mutations. Linkage information, therefore, was not collected for 22 non-Hispanic index cases with a positive family history. For the remaining families, in whom no KRIT1 mutation was identified, highly polymorphic di-, tri-, and tetranucleotide repeat marker loci were genotyped using PCR. Primers for each locus were designed from available published sequences and synthesized by personnel at the Keck Biotechnology Resource Laboratory at Yale University. One primer of each pair was 5Ј tagged with either 6-FAM, HEX, or TET phosphoramidite dyes. The markers used for the three CCM loci were previously described: 5 for CCM1 at 7q22, D7S1813, D7S1789, and D7S646 spanning 5 cM; for CCM2, D7S2846, D7S510, D7S521, D7S667, and D7S478 spanning 22 cM; and for CCM3, D3S3053, GATA81H05, GATA14G12, GGAA3H06, and D3S1262 spanning 22 cM. Genotypes were determined with the aid of an ABI 377 instrument. Pairwise and multipoint linkage analysis was performed, as previously described, 5 
Single-Strand Conformational Polymorphism Analysis and DNA Sequencing
We used SSCP to screen for molecular variants in candidate genes in patients with CCM. In brief, specific primers were used to amplify a segment of genomic DNA containing a coding sequence. The products were labeled by inclusion of 1 Ci of ␣-32 P deoxycytosine triphosphate in the PCR reaction. Products were denatured and then fractionated under denaturing conditions via electrophoresis on three different gels under three empirically derived conditions: 1) 0.5 ϫ MDE gel, 0.6 ϫ TBE buffer, electrophoresis at 50 W constant power at room temperature; 2) 0.5 ϫ MDE gel, 0.6 ϫ TBE buffer, electrophoresis at 50 W at 4˚C; and 3) 5% acrylamide (37.5:1 acrylamide/bis acrylamide) gel, 0.5 ϫ TBE buffer at 15 W at 4˚C. Amplicons were detected by exposure of the gel to x-ray film (Eastman Kodak Co., Rochester, NY). Variant amplicons were excised from the gel and eluted in water. These products were used for a second round of PCR amplification with the same primers, after which the product was subjected to DNA sequence analysis by dideoxyribonucleotide chain termination with the aid of an ABI 373 instrument.
Results
Mutation Analysis
We screened 206 index cases and other affected members of the kindreds for mutations in the KRIT1 gene, including previously unrecognized upstream coding exons identified by blasting the gene sequence against human and mouse Expressed Sequence Tag databases. 8, 20, 26 In 56 of the index cases, the patients were of Hispanic descent and in 150 the patients were of non-Hispanic descent (Fig. 1) . Forty-three of the 56 Hispanic-American index cases of Mexican descent were collected from kindreds living in the US with 21 Thirteen of the remaining 47 kindreds showed a linkage to the CCM1 locus, 12 a linkage to the CCM2 or CCM3 locus, and in 22 the linkage information was not available. Of the 13 kindreds linked to the CCM1 locus, 11 had a posterior probability greater than 0.9 and nine of these had mutations in KRIT1. The two kindreds with a probability less than 0.9 did not have KRIT1 mutations. Among the 22 kindreds with ambiguous or no linkage information, four had independent novel mutations. A total of 12 independent and novel mutations within the KRIT1 gene were found in the 150 non-Hispanic kindreds that were screened.
Of the 56 Hispanic families that were screened, 43 of the kindreds were from the US and 13 were from Mexico. The 43 US kindreds were composed of 21 with a positive family history and 22 without. Of the 21 with a positive family history, 18 had the 2105C➝T founder mutation-leading to a premature stop codon in exon 14-whereas 13 of the 22 kindreds without a family history had the same mutation. None of the 13 families residing in Mexico, the proposed origin of Mexican Americans who have immigrated to the Southwestern US, had this founder mutation. of these having a positive family history of CCM. We identified the Q455X founder mutation in 18 (86%) of these 21 families. No mutation was identified in the remaining three kindreds. Twenty-two remaining cases were apparently sporadic with no known family history. We identified the founder mutation in 13 (59%) of these cases; no mutations were identified in the remaining nine. Every case that had the conserved Hispanic haplotype 11 -with or without family history-had the Q455X founder mutation.
To determine if the founder mutation could be traced back to Mexico, the original source of migration to the southwestern US, 13 Mexican families with CCM from this region were collected and screened. These families did not have the conserved haplotype or the founder mutation.
During our initial screen of the 150 non-Hispanic kindreds, 47 (31%) reported a positive family history. Linkage analysis was performed in 25 of these families in which at least three affected members were available for study; 13 showed evidence of linkage to the CCM1 locus. Eleven of these families had a posterior probability greater than 0.9 for linkage to the KRIT1 locus and we identified mutations in nine of these 11. We found the identical mutation in two presumably independent kindreds; however, further analysis of these two kindreds revealed that they share a common ancestor, suggesting that this mutation was inherited by descent. In the remaining two kindreds among the original 13 with evidence for linkage to the CCM1 locus, we did not identify KRIT1 mutations by SSCP analysis.
In the remaining 22 non-Hispanic kindreds with a positive family history of CCM, we performed KRIT1 mutational analysis on index cases. We identified four novel KRIT1 mutations among these 22 index cases, bringing the total number of independent KRIT1 mutations to 12 (Table  1 and Fig. 3) . Screening of all 103 non-Hispanic persons with CCM and no family history did not identify any new germline mutations in KRIT1 in any of these apparently sporadic cases.
The 12 mutations identified here exist in coding and splice-site sequences throughout the KRIT1 gene (Fig. 4) . All newly identified mutations in the coding sequence, including mutations in apparently sporadic cases, are nonsense, frame-shift, or splice-site variants that prematurely truncate the encoded protein (Table 1 ).
Discussion
The discovery that mutations in KRIT1 lead to CCMs is the first of many steps in understanding the pathogenesis of this disease. Here we report the spectrum of mutations leading to the formation of these lesions in Hispanic and nonHispanic families within our study population. Based on our data, 30% of non-Hispanic families with two or more cases of CCM linked to the CCM1 locus 5 and mutations in KRIT1 have been identified in the majority of these cases in our study population (11 of 13 kindreds). If there are three or more affected members within a CCM kindred, the chance of having a KRIT1 mutation increases to 50%. Among non-Hispanic patients in whom a family history has been rigorously excluded, KRIT1 mutations account for none or very few cases of CCM. For each mutation the ABI instrument-generated chromatogram shown on the left indicates the wild-type sequence. The mutated sequence is displayed to the right of the wild-type one and is designated by bold text above the sequence, with the kindred number listed below.
We did not identify KRIT1 mutations in two of 13 nonHispanic families, despite evidence for linkage to the CCM1 locus. Both of these families were small and the evidence for linkage was inconclusive, with posterior probabilities of linkage lower than 0.9 for linkage to the CCM1 locus. The CCM in these families is most likely attributable to mutations at another locus such as CCM2 or CCM3. Alternatively, these families could have mutations outside the coding sequence of KRIT1 that escaped detection.
Among Hispanic Americans of Mexican descent, a founder mutation in KRIT1 (Q455X), inherited from a common ancestor, is responsible for CCM1 lesions in the majority of cases. A positive family history predicts nearly a 90% chance of having this founder mutation result in CCM. In apparently sporadic cases, 60% are shown to have this founder mutation.
Including the 12 mutations reported in this series, all but one exist in familial cases. 1, 2, 4, 6, 15, 17, 20, 21, 23, 24, 27 In every instance except one, sequencing data have shown nonsense, point, splice-site, or frame-shift mutations leading to premature stop codons, distributed throughout the KRIT1 gene (Fig. 4) .
Interestingly, despite a relatively even distribution throughout the originally identified 12 exons of the KRIT1 gene, only a few of the reported mutations exist in the newly identified 5Ј exons. These new exons are part of a continuous open reading frame with the original 12 KRIT1 exons, but they might represent alternatively spliced species. Only one mutation at 1342C➝G predicts a glycine-toglutamate missense mutation, although it is unclear if this represents a nonfunctional polymorphism or a functional mutation. 6 The other mutations include two frame-shift mutations located at 893delAAAG and 894delAAGT in exon 6, both predicting premature stop codons, 20 and three more mutations (two frame-shift and one substitution mutations) reported by Cave-Riant, et al. 1 Mutations in the KRIT1 gene can lead to a loss of function either through a dominant-negative effect, haploinsufficiency, or a two-hit model. All the mutations identified to date encode a truncated KRIT1 protein. The process of nonsense-mediated messenger RNA decay is expected to lead to degradation of these aberrant transcripts such that the truncated gene products are never produced; 9,18 our preliminary results support this conclusion and make dominant-negative models unlikely. We favor the two-hit model over the haploinsufficiency mechanism for several reasons. In the two-hit model, patients with the inherited form of CCM1 are born with one mutant KRIT1 allele, and one wild-type allele, and lose the second allele through a somatic mutation, ultimately leading to complete loss of KRIT1 expression; only the progeny of these cells develop into CCM1 lesions. In contrast, patients with the sporadic form of CCM are born with two wild-type copies of the KRIT1 gene and have to acquire two independent somatic mutations before CCM lesions develop. One result is that these sporadic cases tend to occur in patients who are older and less likely to have multiple CCM lesions than their familial CCM counterparts. Magnetic resonance imaging of patients with familial and sporadic CCM supports this hypothesis, because it has demonstrated a correlation between the number of lesions and family history, as well as the age of the patient. Patients with the sporadic form of CCM almost always have a single lesion, as opposed to patients with the familial form of the disease, in whom multiple lesions are common and clinical awareness of the disease occurs at earlier ages. Lack of correlation between the location of mutations within the KRIT1 gene and clinical symptomatology is also consistent with the notion that loss of function of both alleles of KRIT1 is necessary for the disease phenotype.
These findings have clinical implications. For example, among Hispanic Americans of Mexican descent, nearly all familial and most sporadic cases will have CCM due to a single mutation inherited from a remote founder. As a result, at-risk relatives can be readily identified prospectively, providing the opportunity for premorbid intervention. Further correlation of the spectrum of mutations in CCM with patient phenotype may permit identification of risk factors at the genomic level. Should molecular markers exist that can identify patients at risk for hemorrhage, neurosurgeons will be able to select candidates more appropriately for treatment with early surgical intervention. Similarly, mutations causing a clinically less severe phenotype may allow for expected management. These genotypephenotype correlation studies for different CCM loci are currently being investigated. 
